Brivudine: Antiviral for Herpes Zoster and the Critical Fluoropyrimidine Interaction
Brivudine is an antiviral drug belonging to the nucleoside analogue class, approved for the early treatment of herpes zoster (shingles) in immunocompetent adults. It is active against varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1) with high selectivity and potency. One of its main practical advantages over older antivirals like aciclovir is the once-daily dosing regimen, which significantly simplifies treatment adherence.
However, brivudine carries an absolute and life-threatening contraindication with fluoropyrimidine cytostatic drugs that every prescriber and patient must know: brivudine is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for the catabolism of 5-fluorouracil (5-FU) and capecitabine. Concurrent use or use within four weeks of fluoropyrimidine chemotherapy can lead to massive accumulation of 5-FU and severe, potentially fatal toxicity. Several patient deaths have been attributed to this interaction in post-marketing experience.
Mechanism of Action
Brivudine is a thymidine analogue that after phosphorylation by viral thymidine kinase (TK) becomes incorporated into viral DNA, where it inhibits viral DNA polymerase. The key feature of its mechanism is the high selectivity for viral over cellular thymidine kinase: brivudine is phosphorylated much more efficiently by VZV and HSV-1 thymidine kinase than by human cellular kinases. This selectivity underpins its favorable therapeutic index in virological terms. Once incorporated into the viral DNA chain, brivudine prevents further elongation of the viral genome. Importantly, its active metabolite bromovinyluracil (BVU) is a powerful irreversible inhibitor of DPD, the enzyme that catabolizes fluorouracil and other fluoropyrimidines. This DPD inhibition is not related to antiviral activity but is the pharmacological basis of the most dangerous drug interaction associated with brivudine.
Indications
Brivudine is approved in the European Union for the treatment of herpes zoster (shingles) in immunocompetent adults when treatment is initiated within 72 hours of rash onset. It is not approved for herpes zoster in immunocompromised patients (those receiving chemotherapy, corticosteroids, or with HIV infection), for herpes simplex labialis, or for varicella (chickenpox). The restriction to immunocompetent patients is important because immunocompromised patients with herpes zoster require intravenous aciclovir rather than oral antivirals for adequate viral suppression. Brivudine is not indicated for ophthalmic zoster as a systemic treatment alone; specialist ophthalmic management is required alongside antiviral therapy in this indication.
Dosage and Administration
The approved dose is 125 mg once daily for seven consecutive days, to be initiated as soon as possible after rash onset and no later than 72 hours after the first lesions appear. The drug is taken orally as a tablet, with or without food. No dose adjustment is required in mild to moderate renal impairment. Use in severe renal impairment and in hepatic impairment has not been adequately studied; caution and medical supervision are required in these populations. Treatment duration is fixed at seven days; no evidence supports extending treatment beyond this period for standard shingles. In zoster ophthalmicus or zoster involving cranial or lumbosacral nerves, specialist evaluation alongside antiviral therapy is strongly recommended.
Side Effects
Brivudine is generally well tolerated in immunocompetent patients. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal discomfort occur in a minority of patients. Elevated liver enzyme levels (transaminases) have been reported and are usually transient. Headache and dizziness occur infrequently. Neurological symptoms, including those of post-herpetic neuralgia, are related to the underlying herpes zoster infection rather than the drug itself. Hypersensitivity reactions are rare. The overall tolerability profile compares favorably with aciclovir, which at the equivalent doses required for VZV often causes higher rates of gastrointestinal side effects.
Interactions
The interaction with fluoropyrimidines is the defining pharmacological danger of brivudine and constitutes an absolute contraindication. Brivudine's metabolite bromovinyluracil (BVU) irreversibly inhibits DPD, the enzyme responsible for degrading 5-fluorouracil (5-FU) and its prodrugs including capecitabine, tegafur, and flucytosine. If a patient on capecitabine or 5-FU-based chemotherapy receives brivudine, 5-FU cannot be adequately catabolized, plasma concentrations rise to toxic levels, and severe toxicity develops including fatal bone marrow aplasia, severe mucositis, and multi-organ failure. The contraindication extends to four weeks before and after brivudine use because DPD inhibition persists beyond the drug's elimination. This four-week window is critical: oncology teams must confirm complete washout before any fluoropyrimidine administration. No dose reduction or monitoring can mitigate this risk; the combination must be avoided entirely. Other interactions are clinically less significant: brivudine does not appear to significantly affect cytochrome P450 enzymes at therapeutic concentrations.
Special Notes
Brivudine is a prescription-only medicine. Before prescribing brivudine, it is essential to take a complete medication history with specific attention to current or recent cytostatic therapy. Patients receiving or recently receiving fluoropyrimidine-based chemotherapy must not be prescribed brivudine under any circumstances. Prescribers should also be aware that some patients are treated with 5-FU-containing combinations that they may not immediately recognize as such (e.g., FOLFOX, FOLFIRI, CAPOX protocols). Brivudine is not recommended during pregnancy due to insufficient data; teratogenic potential cannot be excluded. Use in children and adolescents has not been established. Post-marketing surveillance has confirmed the real-world risk of the fluoropyrimidine interaction, and regulatory authorities have repeatedly reinforced warnings in product information documents across Europe.
Related Active Ingredients
Frequently Asked Questions
Why is brivudine absolutely contraindicated with chemotherapy?
Brivudine's metabolite bromovinyluracil irreversibly inhibits dihydropyrimidine dehydrogenase (DPD), the primary enzyme responsible for breaking down fluoropyrimidine drugs such as 5-FU and capecitabine. Without functional DPD, these chemotherapy drugs accumulate to severely toxic levels, causing fatal bone marrow failure, mucositis, and multi-organ damage. There is no antidote. Even a single dose of brivudine can inhibit DPD for weeks. This contraindication is absolute and non-negotiable.
What is the advantage of brivudine over aciclovir for shingles?
Aciclovir for herpes zoster requires 800 mg five times daily for seven days, totaling 40 doses. Brivudine requires one tablet of 125 mg once daily for seven days, totaling 7 doses. This simplified regimen substantially improves adherence, which is important because early and consistent antiviral treatment reduces both the severity of the acute episode and the risk of post-herpetic neuralgia. Clinically, both achieve similar antiviral efficacy in immunocompetent patients.
How long must one wait between brivudine and chemotherapy?
At least four weeks must pass between the last dose of brivudine and the initiation of any fluoropyrimidine-containing chemotherapy. The DPD enzyme is irreversibly inhibited by brivudine's metabolite and must be resynthesized, which takes approximately four weeks. Conversely, if a patient is stopping chemotherapy to start brivudine for shingles, a four-week gap after the last fluoropyrimidine dose is also required. In an emergency, specialist pharmacological guidance should be sought.
Sources
- EMA: Brivudine (Zostex) EPAR and SmPC, aktueller Stand
- De Clercq E: Brivudin monophosphate: a potent inhibitor of VZV thymidine kinase. Nat Rev Drug Discov 2020
- Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM): Rote-Hand-Brief Brivudin und Fluoropyrimidine 2020